2013-Guide to Clinical Trials for People with Hepatitis C
Updates from The Treatment Action Group (TAG)
This month TAG published an insightful second edition guide to hepatitis C clinical trials, written by Tracy Swan and Matt Sharp.
Guide to Clinical Trials for People with Hepatitis C
January 2013 - There are many new hepatitis C drugs being studied in clinical trials. People with hepatitis C have many options to choose from. Whether you have hepatitis C or another medical condition, deciding to participate in a clinical trial can be complicated. Having more information can help you decide whether or not to participate in a clinical trial, and which trial, or trials, may be right for you. This guide is available in English and Spanish....Continue reading @ TAG
The "2012 Pipeline Report" by HIV i-Base (U.K.) and Treatment Action Group (TAG) (U.S.) was published in July and updated this past December by Tracy Swan, the author writes;
It is difficult to be anything other than dazzled by astounding cure rates of up to 100% from a multitude of interferon-free hepatitis C virus (HCV) clinical trials presented at the American Association for the Study of Liver Diseases (AASLD) meeting in November 2012. Proof of concept has been established: hepatitis C, a disease that claims more than 350,000 lives annually, can be cured with three months of oral antiviral drugs.
These incredible advances bear scrutiny, since most of these interferon-free trials enrolled people with minimal liver disease—many of whom were being treated for the first time. Information about safety, efficacy, and tolerability of interferon-free regimens is needed in other groups, such as people coinfected with HIV, liver transplant candidates and recipients, and people with cirrhosis (especially those who are treatment-experienced)—in other words, people with the greatest immediate need of a safe and highly effective cure.Continue reading...
The Treatment Action Group (TAG) is an independent AIDS research and policy think tank fighting for better treatment, a vaccine, and a cure for AIDS. TAG works to ensure that all people with HIV receive lifesaving treatment, care, and information.
We are science-based treatment activists working to expand and accelerate vital research and effective community engagement with research and policy institutions. TAG catalyzes open collective action by all affected communities, scientists, and policy makers to end AIDS.
TAG is a nonprofit, tax-exempt 501(c)(3) organization. E.I.N. 13-3624785